Last Updated on January 9, 2021 by The Health Master
Amneal Pharmaceuticals announced that it has received approval of an additional strength of 500 mg to its Abbreviated New Drug Application (ANDA), from the US Food and Drug Administration (USFDA) for Abiraterone Acetate Tablets, USP, 250 mg and 500 mg.
This ANDA is approved for its use in combination with Prednisone. Abiraterone Acetate Tablets, USP, 250 mg and 500 mg, are the generic version of Zytiga for treatment of metastatic prostate cancer.
Amneal immediately initiated commercialisation activities upon the approval of the additional 500 mg strength.
According to IQVIA, US annual sales for Abiraterone Tablets, USP, 500 mg, for the 12 months ended November 2020 were approximately $413 million.
Also read | Lupin gets tentative USFDA nod for type 2 diabetes drug
The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.
Follow and connect with us on Facebook and Linkedin
Go to main website, click here
Subscribe for daily free updates, click here
